BLRX
BioLineRx Ltd.
$3.16
+$0.14(+4.64%)
50
Overall
--
Value
58
Tech
42
Quality
Market Cap
$13.27M
Volume
7.86K
52W Range
$2.15 - $5.06
Target Price
$20.33
Company Overview
| Mkt Cap | $13.27M | Price | $3.16 |
| Volume | 7.86K | Change | +4.64% |
| P/E Ratio | -1.4 | Open | $3.02 |
| Revenue | $22.9M | Prev Close | $3.02 |
| Net Income | $-9.2M | 52W Range | $2.15 - $5.06 |
| Div Yield | N/A | Target | $20.33 |
| Overall | 50 | Value | -- |
| Quality | 42 | Technical | 58 |
No chart data available
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)
Howard Kim•18 days ago
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend
TipRanks Auto-Generated Newsdesk•24 days ago
Options Volatility and Implied Earnings Moves This Week, May 26 – May 28, 2026
TipRanks Auto-Generated Newsdesk•25 days ago
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $3.16 | +4.6% | 7.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |